Bile Duct Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019 On 19thDecember 2014
Summary The industry analysis specialist, has released its new report, “Bile Duct Cancer Therapeutics Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Bile Duct Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Bile Duct Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Bile Duct Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-bile-duct-cancer-therapeutics-pipeline-assessment-and-marketforecasts-135240 Scope The report provides information on the key drivers and challenges of the Bile Duct Cancer Therapeutics market. Its scope includes Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Bile Duct Cancer Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. - Analysis of the current and future competition in the seven key countries Bile Duct Cancer Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Bile Duct Cancer Therapeutics market. - Analysis of key recent licensing and partnership agreements in Bile Duct Cancer Therapeutics market
Reasons to buy The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Bile Duct Cancer Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Bile Duct Cancer Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What’s the next big thing in the global Bile Duct Cancer Therapeutics market landscape? – Identify, understand and capitalize. Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Other industries we cover: • • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Discounts on Market Research Reports till 31st December, 2014 For more inquiries, contact at +91 - 998 729 5242 / contact@jsbmarketresearch.com Table of Content 2 Bile Duct Cancer Therapeutics - Introduction 2.1 Overview 2.2 Classification of Bile Duct Cancer 2.3 Epidemiology 2.4 Etiology 2.5 Pathophysiology 2.6 Signs and Symptoms 2.7 Diagnosis 2.7.1 Physical Exam and History 2.7.2 Blood Tests 2.7.3 Diagnostic Imaging Techniques 2.7.4 Other tests 2.8 Staging 2.8.1 TNM Classification 2.9 Treatment 2.9.1 Surgery 2.9.2 Chemotherapy 2.9.3 Radiation Therapy (RT) Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
2.10 Chemotherapy Regimens 2.11 GlobalData Pipeline Report Guidance 3 Bile Duct Cancer Therapeutics - Market Characterization 3.1 Bile Duct Cancer Therapeutics Market Size (2006-2011) – Global 3.2 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) – Global 3.3 Bile Duct Cancer Therapeutics Market Size (2006-2011) – US 3.4 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) – The US 3.5 Bile Duct Cancer Therapeutics Market Size (2006-2011) – The UK 3.6 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) – The UK 3.7 Bile Duct Cancer Therapeutics Market Size (2006-2011) – France 3.8 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) – France 3.9 Bile Duct Cancer Therapeutics Market Size (2006-2011) – Germany 3.10 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) – Germany 3.11 Bile Duct Cancer Therapeutics Market Size (2006-2011) – Italy 3.12 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) – Italy 3.13 Bile Duct Cancer Therapeutics Market Size (2006-2011) – Spain 3.14 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) – Spain 3.15 Bile Duct Cancer Therapeutics Market Size (2006-2011) – Japan 3.16 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) – Japan 3.17 Drivers and Barriers for the Bile Duct Cancer Therapeutics Market 3.17.1 Drivers for the Bile Duct Cancer Therapeutics Market 3.17.2 Barriers for the Bile Duct Cancer Therapeutics Market 3.18 Key Events Impacting the Future Market 3.18.1 Opportunity and Unmet Need 3.19 Key Takeaway 4 Bile Duct Cancer Therapeutics Market - Competitive Assessment 4.1 Overview 4.1.1 Strategic Competitor Assessment 4.2 Profiles of the Commonly Used Products in the Bile Duct Cancer Therapeutics Market 4.2.1 Gemcitabine 4.2.2 Gemcitabine and Oxaliplatin (GEMOX) 4.2.3 Gemcitabine and Cisplatin 4.2.4 Gemcitabine and Capecitabine 4.3 Key Takeaway 5 Bile Duct Cancer Therapeutics Market - Pipeline Assessment 5.1 Overview 5.2 Strategic Pipeline Assessment 5.3 Bile Duct Cancer Pipeline Analysis – Pipeline by Clinical Phases of Development 5.3.1 Bile Duct Cancer Therapeutics – Phase III Pipeline Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
5.3.2 Bile Duct Cancer Therapeutics – Phase II Pipeline 5.3.3 Bile Duct Cancer Therapeutics – Phase I/II Pipeline 5.3.4 Bile Duct Cancer Therapeutics – Phase I Pipeline 5.3.5 Bile Duct Cancer Therapeutics – Preclinical Pipeline 5.4 Bile Duct Cancer Pipeline by Mechanism of Action 5.5 Bile Duct Cancer Technology Trends Analytical Framework 5.6 Molecule Profile for Selected Drugs under Clinical Development 5.6.1 Caprelsa (vandetanib) 5.6.2 OTS102 (elpamotide) 5.6.3 S-1 (tegafur, gimeracil and oteracil) 5.7 Key Takeaway 6 Bile Duct Cancer Therapeutics – Clinical Trials Mapping 6.1 Clinical Trials by Country (US, EU5 and Japan) 6.2 Clinical Trials Mapping by Phase 6.3 Clinical Trials Mapping by Trial Status 6.4 Overall Sponsors 6.5 Prominent Sponsors 6.6 Top Companies Participating in Bile Duct Cancer Therapeutics Clinical Trials 7 Bile Duct Cancer Therapeutics - Strategic Assessment 7.1 Future Market Competition Scenario 8 Bile Duct Cancer Therapeutics - Future Players in The Market 8.1 Introduction 8.2 Company Profiles 8.2.1 AstraZeneca PLC 8.2.2 Otsuka Pharmaceutical Co. Ltd. (OPC) 9 Bile Duct Cancer Therapeutics - Licensing and Partnership Deals 10 Bile Duct Cancer Therapeutics - Appendix 10.1 Definitions 10.2 Acronyms 10.3 Methodology 10.3.1 Coverage 10.3.2 Secondary Research 10.3.3 Forecasting 10.3.4 Primary Research 10.3.5 Expert Panel Validation 10.4 Contact Us 10.5 Disclaimer 10.6 Bibliography Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
List Of Tables Table 1: Survival Rates of Bile Duct Cancer Table 2: Prevalence of Bile Duct Cancer in Major Markets Table 3: Intrahepatic Bile Duct Cancer, TNM Definitions Table 4: Intrahepatic Bile Duct Cancer, Stage Grouping Table 5: Perihilar Bile Duct Cancer, TNM Definitions Table 6: Perihilar Bile Duct Cancer, Stage Grouping Table 7: Distal Bile Duct Cancer, TNM Definitions Table 8: Distal Bile Duct Cancer, Stage Grouping Table 9: Bile Duct Cancer Chemotherapy regimens Table 10: Bile Duct Cancer Therapeutics Market, Global, Revenue ($m), 2006–2011 Table 11: Bile Duct Cancer Therapeutics Market, Global, Forecast ($m), 2011–2019 Table 12: Bile Duct Cancer Therapeutics Market, The US, Revenue ($m), 2006–2011 Table 13: Bile Duct Cancer Therapeutics Market, The US, Revenue ($m), 2011–2019 Table 14: Bile Duct Cancer Therapeutics Market, The UK, Revenue ($m), 2006–2011 Table 15: Bile Duct Cancer Therapeutics Market, The UK, Forecast ($m), 2011–2019 Table 16: Bile Duct Cancer Therapeutics Market, France, Revenue ($m), 2006–2011 Table 17: Bile Duct Cancer Therapeutics Market, France, Forecast ($m), 2011–2019 Table 18: Bile Duct Cancer Therapeutics Market, Germany, Revenue ($m), 2006–2011 Table 19: Bile Duct Cancer Therapeutics Market, Germany, Forecast ($m), 2011–2019 Table 20: Bile Duct Cancer Therapeutics Market, Italy, Revenue ($m), 2006–2011 Table 21: Bile Duct Cancer Therapeutics Market, Italy, Forecast ($m), 2011–2019 Table 22: Bile Duct Cancer Therapeutics Market, Spain, Revenue ($m), 2006–2011 Table 23: Bile Duct Cancer Therapeutics Market, Spain, Forecast ($m), 2011–2019 Table 24: Bile Duct Cancer Therapeutics Market, Japan, Revenue ($m), 2006–2011 Table 25: Bile Duct Cancer Therapeutics Market, Japan, Forecast ($m), 2011–2019 Table 26: Bile Duct Cancer Therapeutics – Phase III Pipeline Table 27: Bile Duct Cancer Therapeutics – Phase II Pipeline Table 28: Bile Duct Cancer Therapeutics – Phase I/II Pipeline Table 29: Bile Duct Cancer Therapeutics – Phase I Pipeline Table 30: Bile Duct Cancer Therapeutics – Preclinical Pipeline Table 31: Bile Duct Cancer Therapeutics – Clinical Trials by Country, 2011 Table 32: Bile Duct Cancer Therapeutics – Clinical Trials by Phase, 2011 Table 33: Bile Duct Cancer Therapeutics – Clinical Trials by Status, 2011 Table 34: Bile Duct Cancer Therapeutics - Clinical Trials by Overall Sponsors, 2011 Table 35: Bile Duct Cancer Therapeutics – Clinical Trials by Prominent Sponsors, 2011 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 36: Bile Duct Cancer Therapeutics Clinical Trial - Company Sponsors by Phase, 2011 Table 37: AstraZeneca – Bile Duct Cancer Pipeline Table 38: Otsuka Pharmaceutical Co. Ltd – Bile Duct Cancer Pipeline Table 39: OA Therapeutics: Licensing and Partnership Deals
List Of Figures Figure 1: Anatomy of the Bile Duct Figure 2: Classification of Bile Duct Cancer Figure 3: Anatomy of the Intrahepatic and Extrahepatic Bile Duct Figure 4: Endoscopic Retrograde Cholangiopancreatography (ERCP) Figure 5: Percutaneous Transhepatic Cholangiography (PTC) Figure 6: Bile Duct Cancer Therapeutics Market, Global, Revenue ($m), 2006–2011 Figure 7: Bile Duct Cancer Therapeutics, Market Share ($m), 2011 Figure 8: Bile Duct Cancer Therapeutics Market, Global, Forecast ($m), 2011–2019 Figure 9: Bile Duct Cancer Therapeutics, Market Share ($m), 2019 Figure 10: Bile Duct Cancer Therapeutics Market, The US, Revenue ($m), 2006–2011 Figure 11: Bile Duct Cancer Therapeutics Market, The US, Forecast ($m), 2011–2019 Figure 12: Bile Duct Cancer Therapeutics Market, The UK, Revenue ($m), 2006–2011 Figure 13: Bile Duct Cancer Therapeutics, The UK, Forecast ($m), 2011–2019 Figure 14: Bile Duct Cancer Therapeutics Market, France, Revenue ($m), 2006–2011 Figure 15: Bile Duct Cancer Therapeutics Market, France, Forecast ($m), 2011-2019 Figure 16: Bile Duct Cancer Therapeutics Market, Germany, Revenue ($m), 2006–2011 Figure 17: Bile Duct Cancer Therapeutics Market, Germany, Forecast ($m), 2011-2019 Figure 18: Bile Duct Cancer Therapeutics Market, Italy, Revenue ($m), 2006–2011 Figure 19: Bile Duct Cancer Therapeutics Market, Italy, Forecast ($m), 2011–2019 Figure 20: Bile Duct Cancer Therapeutics Market, Spain, Revenue ($m), 2006–2011 Figure 21: Bile Duct Cancer Therapeutics Market, Spain, Forecast ($m), 2011–2019 Figure 22: Bile Duct Cancer Therapeutics Market, Japan, Revenue ($m), 2006–2011 Figure 23: Bile Duct Cancer Therapeutics Market, Japan, Forecast ($m), 2011–2019 Figure 24: Bile Duct Cancer Therapeutics, Key Events Impacting the Future Market, 2011 Figure 25: Opportunity and Unmet Need in the Bile Duct Cancer Therapeutics Market, 2011 Figure 26: Bile Duct Cancer Therapeutics Market– Strategic Competitor Assessment, 2011 Figure 27: Bile Duct Cancer Therapeutics - Pipeline by Phase of Clinical Development, 2011 Figure 28: Bile Duct Cancer Therapeutics – Clinical Pipeline by Mechanism Of Action, 2011 Figure 29: Bile Duct Cancer Therapeutics - Technology Trends Analytical Framework, 2011 Figure 30: Bile Duct Cancer Therapeutics - Technology Trends Analytical Framework – Description, 2011 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Figure 31: Bile Duct Cancer Therapeutics – Clinical Trials by Country, 2011 Figure 32: Bile Duct Cancer Therapeutics – Clinical Trials by Phase, 2011 Figure 33: Bile Duct Cancer Therapeutics – Clinical Trials by Status, 2011 Figure 34: Bile Duct Cancer Therapeutics – Clinical Trials by Overall Sponsors, 2011 Figure 35: Bile Duct Cancer Therapeutics – Clinical Trials by Prominent Sponsors, 2011 Figure 36: Bile Duct Cancer Therapeutics Clinical Trial - Company Sponsors by Phase, 2011 Figure 37: Bile Duct Cancer Therapeutics, Strategic Assessment, 2011 Figure 38: Bile Duct Cancer Therapeutics Market – Clinical Pipeline by Company, 2011 Figure 39: GlobalData Market Forecasting Model
Report Price: Licence Type
Price
$ 3995
Site Licence
$ 7990
Enterprise Wide Licence
$ 11985
Related Reports: Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Unstable Angina Therapeutics - Pipeline Assessment and Market Forecast to 2018 Venous Thromboembolism (VTE) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Pancreatitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Polycythemia Vera Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Athletes Foot Therapeutics - Pipeline Assessment and Market Forecasts to 2019
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on Bile Duct Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019 http://www.jsbmarketresearch.com/healthcare-medical/r-bile-duct-cancertherapeutics-pipeline-assessment-and-market-forecasts-135240
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/